Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
Race to deliver therapies directly to the heart

Race to deliver therapies directly to the heart

New Capabilities

FDA accepts Helix catheter review as BioCardia pursues parallel approval tracks for device and therapy

April 28th, 2026: Japanese Patent Allowed for Heart3D Fusion Imaging Software

Overview

In March 2026, the FDA accepted BioCardia's pre-submission package for the Helix Transendocardial Delivery Catheter, the first catheter that injects cell and gene therapies directly into heart muscle, and scheduled a formal meeting for Q2 2026. The device, backed by fifteen clinical trials, uses a small helical needle anchored within the beating heart to precisely deliver therapeutic agents to damaged tissue; CDRH leads the review in consultation with CBER.

BioCardia is pursuing two regulatory tracks: alongside the Helix device review, it submitted CardiAMP Heart Failure trial data to the FDA in April 2026 and requested a Q2 meeting to explore accelerated approval for CardiAMP, a therapy using bone marrow cells to repair heart tissue. Echocardiography data from March's Technology and Heart Failure Therapeutics conference in Boston showed the therapy reduces pathological left ventricular remodeling, a sign the heart is rebuilding rather than deteriorating further. The company ended 2025 with approximately $2.5 million in cash and no revenues.

Why it matters

Clearing the delivery device would unlock an entire generation of cardiac cell and gene therapies for the 6 million Americans living with heart failure.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict

Key Indicators

15
Clinical trials supporting approval
BioCardia's FDA submission includes safety and efficacy data from fifteen controlled studies
425,147
Annual U.S. deaths involving heart failure
Heart failure contributed to nearly half of all cardiovascular deaths in 2022
11%
Cell retention with intramyocardial delivery
Direct injection retains nearly four times more cells than intracoronary delivery
47%
Reduction in heart death equivalents
BioCardia's CardiAMP therapy showed this reduction in phase 3 trial results

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 5 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Organizations Involved

Timeline

January 1999 April 2026

13 events Latest: April 28th, 2026 · 1 month ago Showing 8 of 13
Tap a bar to jump to that date
  1. Japanese Patent Allowed for Heart3D Fusion Imaging Software

    Latest Corporate

    Japan allows BioCardia's patent covering its Heart3D Fusion Imaging software used for procedure planning and real-time navigation during CardiAMP procedures; BioCardia reports positive consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on a potential approval submission.

  2. BioCardia Files for FDA Meeting on CardiAMP Accelerated Approval

    Regulatory

    BioCardia submits CardiAMP HF clinical study data to FDA and requests a Q2 2026 meeting to discuss the accelerated approval pathway for the CardiAMP System in ischemic heart failure with reduced ejection fraction, under its Breakthrough Designation.

  3. BioCardia Reports 2025 Annual Results with $2.5M Cash

    Corporate

    BioCardia reports 2025 annual financial results: net loss of $8.2 million, R&D expenses of $5.0 million, zero revenues, and cash of approximately $2.5 million at year-end.

  4. FDA Accepts Helix Pre-Submission Package for Substantive Review

    Regulatory

    FDA accepts BioCardia's Helix Transendocardial Delivery Catheter pre-submission package, confirming it contains all necessary elements for substantive review; formal Q2 2026 review meeting scheduled; CDRH leads in consultation with CBER.

  5. CardiAMP Echocardiography Data Presented at THT Conference

    Clinical Trial

    Late-breaking echocardiography results from the CardiAMP HF trial presented at Technology and Heart Failure Therapeutics (THT) in Boston show cell therapy patients demonstrated statistically significant reductions in pathological left ventricular remodeling versus controls, particularly in the elevated-biomarker subgroup.

  6. FDA Pre-Submission Filed for Helix Catheter

    Regulatory

    BioCardia files Pre-Submission with FDA seeking approval of Helix Transendocardial Delivery Catheter, supported by data from 15 clinical trials under Breakthrough Designation.

  7. Two-Year Trial Results Show 47% Reduction in Deaths

    Clinical Trial

    BioCardia announces two-year outcomes from Phase 3 CardiAMP-HF study showing 47% relative risk reduction in heart death equivalents and improved quality of life.

  8. Phase 3 Trial Completed

    Clinical Trial

    BioCardia completes Phase 3 randomized double-blind controlled trial of autologous cell therapy for ischemic heart failure with 115 patients across 18 centers.

  9. FDA Approves Protocol Amendment

    Regulatory

    FDA approves CardiAMP Heart Failure II protocol amendment to use proprietary cell population analysis screening to define treatment.

  10. Positive Interim Phase 3 Results

    Clinical Trial

    BioCardia reports positive interim results from CardiAMP-HF trial showing 86% relative risk reduction in heart death equivalents in patients with elevated biomarkers.

  11. BioCardia Goes Public

    Corporate

    BioCardia becomes a publicly traded company through a reverse merger with Tiger X Medical.

  12. Early Transendocardial Injection Studies

    Research

    First clinical studies using catheter-based transendocardial injection of skeletal myoblasts in heart failure patients demonstrate feasibility of the approach.

  13. BioCardia Founded

    Corporate

    Dr. Simon Stertzer and colleagues establish BioCardia in San Carlos, California, to develop biointerventional cardiology technologies.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

June 2003

First Autologous Stem Cell Heart Injection (2003)

French surgeon Philippe Menasché performed the first clinical injection of autologous skeletal myoblasts into human heart muscle using catheter-based delivery. Five patients with ischemic heart failure received cells via the MyoStar NOGA-guided catheter system. The procedure demonstrated feasibility but raised questions about arrhythmia risks.

Then

The pilot study showed the approach was technically possible, with improvements in heart function observed at six-month follow-up.

Now

This pioneering work launched two decades of clinical trials exploring catheter-based cell delivery to the heart, establishing transendocardial injection as a viable approach despite ongoing safety refinements.

Why this matters now

BioCardia's Helix catheter represents the culmination of this 20+ year development arc—the first attempt to gain regulatory approval for a device category that has existed only in research settings.

1997-2005

Biosense Webster NOGA System Development (1997-2005)

Biosense Webster developed the NOGA electromechanical mapping system with the MyoStar injection catheter, creating the first commercial platform for targeted intramyocardial injection. The system could construct three-dimensional heart maps and guide needle placement to specific regions of damaged tissue.

Then

The technology enabled dozens of clinical trials investigating cell therapy for cardiac disease, establishing proof of concept for targeted delivery.

Now

While the NOGA/MyoStar system was never approved specifically as a therapy delivery device, it proved the technological foundation that BioCardia and others built upon.

Why this matters now

The Helix catheter is designed as a dedicated delivery system rather than a mapping tool with injection capability, representing a shift from research-focused devices to a commercial therapeutic platform.

2014-2022

REGENERATE Trials and Delivery Method Debate (2014-2022)

The REGENERATE-IHD and REGENERATE-DCM trials directly compared intracoronary delivery (through coronary arteries) versus intramyocardial delivery (directly into heart muscle) in 60+ patients with chronic heart failure. Researchers sought to determine whether the technically simpler intracoronary approach could match the cell retention of direct injection.

Then

Studies found intramyocardial injection retained about 11% of delivered cells versus 3% for intracoronary delivery—a significant difference for therapeutic efficacy.

Now

The data reinforced the clinical rationale for transendocardial delivery systems like Helix, demonstrating that the added procedural complexity produces meaningfully better cell retention.

Why this matters now

This body of evidence supports BioCardia's FDA application by showing that transendocardial delivery is not just one option among equals—it appears to be the superior approach for getting therapeutic cells where they need to go.

Sources

(14)